ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts

Nat Immunol. 2022 Sep;23(9):1330-1341. doi: 10.1038/s41590-022-01285-0. Epub 2022 Aug 23.

Abstract

Fibroblasts, the most abundant structural cells, exert homeostatic functions but also drive disease pathogenesis. Single-cell technologies have illuminated the shared characteristics of pathogenic fibroblasts in multiple diseases including autoimmune arthritis, cancer and inflammatory colitis. However, the molecular mechanisms underlying the disease-associated fibroblast phenotypes remain largely unclear. Here, we identify ETS1 as the key transcription factor governing the pathological tissue-remodeling programs in fibroblasts. In arthritis, ETS1 drives polarization toward tissue-destructive fibroblasts by orchestrating hitherto undescribed regulatory elements of the osteoclast differentiation factor receptor activator of nuclear factor-κB ligand (RANKL) as well as matrix metalloproteinases. Fibroblast-specific ETS1 deletion resulted in ameliorated bone and cartilage damage under arthritic conditions without affecting the inflammation level. Cross-tissue fibroblast single-cell data analyses and genetic loss-of-function experiments lent support to the notion that ETS1 defines the perturbation-specific fibroblasts shared among various disease settings. These findings provide a mechanistic basis for pathogenic fibroblast polarization and have important therapeutic implications.

MeSH terms

  • Arthritis, Rheumatoid* / metabolism
  • Arthritis, Rheumatoid* / pathology
  • Fibroblasts* / metabolism
  • Fibroblasts* / pathology
  • Humans
  • Matrix Metalloproteinases / metabolism
  • Proto-Oncogene Protein c-ets-1* / genetics
  • Proto-Oncogene Protein c-ets-1* / metabolism
  • RANK Ligand / genetics
  • Transcription Factors / metabolism

Substances

  • ETS1 protein, human
  • Proto-Oncogene Protein c-ets-1
  • RANK Ligand
  • Transcription Factors
  • Matrix Metalloproteinases